210 related articles for article (PubMed ID: 15334243)
61. Practice Patterns and Barriers in Botulinum Toxin Injection for the Treatment of Voice Disorders.
McGarey PO; Simpson CB; Daniero JJ
J Voice; 2022 Jan; 36(1):113-118. PubMed ID: 32467003
[TBL] [Abstract][Full Text] [Related]
62. Longitudinal effects of botulinum toxin injections on voice-related quality of life (V-RQOL) for patients with adductory spasmodic dysphonia.
Hogikyan ND; Wodchis WP; Spak C; Kileny PR
J Voice; 2001 Dec; 15(4):576-86. PubMed ID: 11792036
[TBL] [Abstract][Full Text] [Related]
63. [Spasmodic dysphonia. Investigation and therapeutic methods].
Marion MH; Klap P; Perrin A; Elbaz E
Rev Neurol (Paris); 1992; 148(3):180-3. PubMed ID: 1604131
[TBL] [Abstract][Full Text] [Related]
64. Prospective study of patients' subjective responses to botulinum toxin injection for spasmodic dysphonia.
Liu TC; Irish JC; Adams SG; Durkin LC; Hunt EJ
J Otolaryngol; 1996 Apr; 25(2):66-74. PubMed ID: 8683655
[TBL] [Abstract][Full Text] [Related]
65. Localized injections of botulinum toxin for the treatment of focal laryngeal dystonia (spastic dysphonia).
Blitzer A; Brin MF; Fahn S; Lovelace RE
Laryngoscope; 1988 Feb; 98(2):193-7. PubMed ID: 3339931
[TBL] [Abstract][Full Text] [Related]
66. Outcomes assessment following treatment of spasmodic dysphonia with botulinum toxin.
Courey MS; Garrett CG; Billante CR; Stone RE; Portell MD; Smith TL; Netterville JL
Ann Otol Rhinol Laryngol; 2000 Sep; 109(9):819-22. PubMed ID: 11007083
[TBL] [Abstract][Full Text] [Related]
67. Evidence for the effectiveness of botulinum toxin for spasmodic dysphonia from high-quality research designs.
Watts CR; Truong DD; Nye C
J Neural Transm (Vienna); 2008; 115(4):625-30. PubMed ID: 17564757
[TBL] [Abstract][Full Text] [Related]
68. [Botulinum toxin: clinical uses and anesthetic implications].
Vidal-Marcos A; Sanz-García M; Infante-Crespo B; Ruiz-Castro M; Rustarazo-Pérez MT; Palma-Gámiz MA
Rev Esp Anestesiol Reanim; 1996; 43(6):208-11. PubMed ID: 8756235
[TBL] [Abstract][Full Text] [Related]
69. Effects of botulinum toxin injections on speech in adductor spasmodic dysphonia.
Ludlow CL; Naunton RF; Sedory SE; Schulz GM; Hallett M
Neurology; 1988 Aug; 38(8):1220-5. PubMed ID: 3399071
[TBL] [Abstract][Full Text] [Related]
70. Laryngeal electromyography in adults with Parkinson's disease and voice complaints.
Zarzur AP; Duprat AC; Shinzato G; Eckley CA
Laryngoscope; 2007 May; 117(5):831-4. PubMed ID: 17473678
[TBL] [Abstract][Full Text] [Related]
71. Case studies in movement disorders.
Evidente VG; Caviness JN; Adler CH
Semin Neurol; 2003 Sep; 23(3):277-84. PubMed ID: 14722823
[TBL] [Abstract][Full Text] [Related]
72. Laryngeal Botulinum Toxin Injection for Vocal Tremor: Utility of Concurrent Strap Muscle Injection.
Nelson RC; Silva Merea V; Tierney WS; Milstein C; Benninger MS; Bryson PC
Laryngoscope; 2019 Jun; 129(6):1433-1437. PubMed ID: 30588631
[TBL] [Abstract][Full Text] [Related]
73. Muscle selection for treatment of cervical dystonia with botulinum toxin--a systematic review.
Nijmeijer SW; Koelman JH; Kamphuis DJ; Tijssen MA
Parkinsonism Relat Disord; 2012 Jul; 18(6):731-6. PubMed ID: 22575237
[TBL] [Abstract][Full Text] [Related]
74. [Diagnostic and therapeutic difficulties in laryngeal dystonia].
Niebudek-Bogusz E; Modzelewska-Radwan B; Pietruszewska W; Zielińska M; Gryczyński M
Otolaryngol Pol; 2003; 57(5):739-45. PubMed ID: 14994622
[TBL] [Abstract][Full Text] [Related]
75. Clinical characteristics of essential voice tremor: a study of 34 cases.
Sulica L; Louis ED
Laryngoscope; 2010 Mar; 120(3):516-28. PubMed ID: 20066728
[TBL] [Abstract][Full Text] [Related]
76. Alterations in CNS activity induced by botulinum toxin treatment in spasmodic dysphonia: an H215O PET study.
Ali SO; Thomassen M; Schulz GM; Hosey LA; Varga M; Ludlow CL; Braun AR
J Speech Lang Hear Res; 2006 Oct; 49(5):1127-46. PubMed ID: 17077220
[TBL] [Abstract][Full Text] [Related]
77. Comparison of botulinum toxin injection procedures in adductor spasmodic dysphonia.
Adams SG; Hunt EJ; Irish JC; Charles DA; Lang AE; Durkin LC; Wong DL
J Otolaryngol; 1995 Dec; 24(6):345-51. PubMed ID: 8699600
[TBL] [Abstract][Full Text] [Related]
78. Injection of botulinum toxin type B for the treatment of otolaryngology patients with secondary treatment failure of botulinum toxin type A.
Guntinas-Lichius O
Laryngoscope; 2003 Apr; 113(4):743-5. PubMed ID: 12671439
[No Abstract] [Full Text] [Related]
79. Botulinum toxin in movement disorders.
Papapetropoulos S; Singer C
Semin Neurol; 2007 Apr; 27(2):183-94. PubMed ID: 17390263
[TBL] [Abstract][Full Text] [Related]
80. An update on the neurologic applications of botulinum toxins.
Evidente VG; Adler CH
Curr Neurol Neurosci Rep; 2010 Sep; 10(5):338-44. PubMed ID: 20567945
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
